Skip to main content
. Author manuscript; available in PMC: 2017 Oct 20.
Published in final edited form as: Histopathology. 2015 Dec 17;68(6):916–924. doi: 10.1111/his.12878

Table 4. Adjuvant therapy risk assessment.

Risk level Radiotherapy Chemotherapy
Low risk, n (%) 7 (17) 27 (64)
Intermediate risk, n (%) 11 (26) NA
High risk, n (%) 24 (57) 15 (36)

NA.

For all tumours that are stage I, n = 42.

Radiotherapy risk assessment was assessed on the basis of zero risk factors (low), one risk factor (intermediate), or at least two (high) of the following risk factors: grade 3 endometrioid or non-endometrioid histotype; at least outer-half myometrial invasion; lymphovascular invasion.

Chemotherapy risk assessment was assessed on the basis of one (low) or two (high) of the following risk factors: grade 3 endometrioid or non-endometrioid histotype; at least deep myometrial invasion.